B¼¼Æ÷ °í°¥ : Innovation Insights
Innovation Insights: B-cell Depletion
»óǰÄÚµå : 1635746
¸®¼­Ä¡»ç : GlobalData
¹ßÇàÀÏ : 2024³â 12¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 55 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 2,499 £Ü 3,615,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 4,998 £Ü 7,231,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,497 £Ü 10,847,000
PDF (Global License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷(ÇØ¿Ü)ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

B¼¼Æ÷ °í°¥Àº ÀÚ°¡¸é¿ªÁúȯ ¹× ƯÁ¤ ¾Ï¿¡¼­ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ´Â B ¸²ÇÁ±¸ÀÇ ¼ö¸¦ °¨¼Ò½ÃŰ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â Ä¡·á Àü·«ÀÔ´Ï´Ù. ÀÌ Á¢±Ù¹ýÀº ÁÖ·Î ·ù¸¶Æ¼½º °üÀý¿°, ´Ù¹ß¼º °æÈ­Áõ, Àü½Å¼º È«¹Ý¼º ·çǪ½º µîÀÇ Áúȯ Ä¡·á¿¡ »ç¿ëµÇ¸ç, B¼¼Æ÷´Â ÀÚ°¡ Ç×ü¸¦ »ý¼ºÇϰí Ç׿øÀ» Á¦½ÃÇÏ¸ç »çÀÌÅäÄ«ÀÎÀ» ºÐºñÇÏ¿© Áúº´¿¡ °ü¿©ÇÕ´Ï´Ù. Ä¡·á¹ýÀº ¸®Åö½Ã¸¿°ú °°Àº ´ÜŬ·ÐÇ×ü¸¦ ÀÌ¿ëÇÏ¿© B¼¼Æ÷ÀÇ Ç¥ÁöÀÚÀÎ CD20À» Ç¥ÀûÀ¸·Î »ï´Â °æ¿ì°¡ ¸¹½À´Ï´Ù. ±×·¯³ª ÀÌ·¯ÇÑ Ä¡·á¹ýÀº ÀϹÝÀûÀ¸·Î ÀÚ°¡ Ç×ü¸¦ °è¼Ó »ý»êÇÒ ¼ö ÀÖ´Â ¼ö¸íÀÌ ±ä ÇüÁú¼¼Æ÷¿¡´Â ÀÛ¿ëÇÏÁö ¾Ê½À´Ï´Ù. Ű¸Þ¶ó Ç׿ø ¼ö¿ëü(CAR) T ¼¼Æ÷¸¦ Æ÷ÇÔÇÑ »õ·Î¿î Ä¡·á¹ýÀº CD19¸¦ Ç¥ÀûÀ¸·Î ÇÏ¿© ´õ ±íÀº B ¼¼Æ÷ °í°¥À» ´Þ¼ºÇϰí, ¼øÁøÇÑ B ¼¼Æ÷¿Í ¸Þ¸ð¸® B ¼¼Æ÷, ±×¸®°í ¼ö¸íÀÌ ÂªÀº ÇüÁú ¼¼Æ÷¿¡ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ƯÇã, ¾à¹°, ÀÓ»ó½ÃÇè, °Å·¡ µ¥ÀÌÅ͸¦ Æ÷ÇÔÇÑ º» º¸°í¼­´Â B¼¼Æ÷ °í°¥ Ä¡·áÀÇ ÇöȲ°ú ÇâÈÄ ¹æÇ⼺À» Æ÷°ýÀûÀ¸·Î Á¶¸ÁÇϰí ÀÖ½À´Ï´Ù.

B¼¼Æ÷ °í°¥ Ä¡·á´Â Á¦¾à ¾÷°è¿¡¼­ ¸Å¿ì ¿µÇâ·Â ÀÖ´Â Çõ½Å ºÐ¾ßÀ̸ç, ƯÈ÷ Roche¿Í °°Àº ´ëÇü Á¦¾à»çº° ƯÇã Ãâ¿ø °Ç¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÃÖ±Ù ÀÌ ºÐ¾ßÀÇ Æ¯Ç㸦 ½Å±Ô·Î Ãâ¿øÇÏ´Â ±â¾÷Àº °¨¼ÒÇϰí ÀÖÁö¸¸, ½Å°æÁúȯ, ÀÚ°¡¸é¿ªÁúȯ, Èñ±ÍÁúȯ µî »õ·Î¿î ÀûÀÀÁõ¿¡ ´ëÇÑ ¿¬±¸°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.

°æÀï Á¤º¸ Ãø¸é¿¡¼­ º¼ ¶§, B¼¼Æ÷ °¨¼Ò ¿ä¹ý¿¡ °ü·ÃµÈ 50°³ ÀÌ»óÀÇ ´ëÇü Á¦¾àȸ»ç°¡ ÀÖÀ¸¸ç, Gilead Sciences, BMS, Roche, Regeneron µîÀÌ °­·ÂÇÑ Çõ½Å Æ÷Æ®Æú¸®¿À¸¦ º¸À¯Çϰí ÀÖ½À´Ï´Ù. Ãʱâ Àμö¿Í Àü·«Àû Á¦ÈÞ°¡ ÀÌ ºÐ¾ßÀÇ Çõ½ÅÀ» ÁÖµµÇϰí ÀÖÀ¸¸ç, Áß±¹¿¡¼­µµ 50°³ ÀÌ»óÀÇ ±â¾÷ ¹× ¿¬±¸±â°üÀÌ Çõ½Å¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

½Å»ý ±â¾÷ Áß¿¡¼­´Â Abelzeta, Nanjing IASO, Ossianix°¡ Çõ½ÅÀÇ ¿µÇâ·Â°ú ÁýÁß·Â Ãø¸é¿¡¼­ ¼±µÎ¸¦ ´Þ¸®°í ÀÖÀ¸¸ç, B¼¼Æ÷ °í°¥ Ä¡·áÁ¦ÀÇ ¾à¹° »óȲÀº ¾Ï Ä¡·á¿Í ¸é¿ª¿ä¹ýÀ» Áß½ÉÀ¸·Î ÇÑ Çõ½Å ÀǾàǰÀÌ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. Squibb, Novartis¿Í °°Àº ´ë±â¾÷µéÀÌ Æ¯È÷ ÀÓ»ó 1»ó ¹× ÀÓ»ó 2»ó ½ÃÇè¿¡¼­ ÀǾàǰ °³¹ßÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.

ÀÓ»ó½ÃÇèÀº ÅØ»ç½º´ëÇб³ MD ¾Ø´õ½¼ ¾Ï¼¾ÅͰ¡ °¡Àå ¸¹Àº ÀÓ»ó½ÃÇèÀ» ÁøÇàÇϰí ÀÖÀ¸¸ç, FF. Hoffmann-La Roche Ltd.°¡ ±× µÚ¸¦ ÀÕ°í ÀÖ½À´Ï´Ù. ¸é¿ªÇÐ ºÐ¾ß ÀÓ»ó½ÃÇèÀÌ ´ëºÎºÐÀ» Â÷ÁöÇϰí ÀÖÀ¸¸ç, ¹Ì¸¸¼º ´ë¼¼Æ÷¼º B¼¼Æ÷ ¸²ÇÁÁ¾ÀÌ °¡Àå ¸¹Àº ÀûÀÀÁõÀ» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ÅõÀÚ È°µ¿ Ãø¸é¿¡¼­´Â B¼¼Æ÷ °¨¼Ò ºÐ¾ß¿¡¼­ 622°Ç, ÃÑ 2,620¾ï ´Þ·¯ ±Ô¸ðÀÇ °Å·¡°¡ ÀÌ·ç¾îÁ³À¸¸ç, ¾ÆÀÏ·£µå¿Í ¹Ì±¹ÀÌ °Å·¡·®°ú ±Ý¾× ¸é¿¡¼­ ÁÖ¿ä Áö¿ªÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ½ÃÀåÀº ÃÖ±Ù ¸î ³â µ¿¾È Á¶Á¤°ú Àü·«Àû ÅëÇÕÀÇ Á¶ÁüÀ» º¸À̰í ÀÖ½À´Ï´Ù.

Roche¿Í °°Àº ´ëÇü Á¦¾àȸ»çµéÀÌ B¼¼Æ÷ °¨¼Ò Ä¡·áÁ¦ÀÇ Æ¯Çã Ȱµ¿¿¡¼­ ¿ìÀ§¸¦ Á¡Çϰí ÀÖÀ¸¸ç, ÃÖ±Ù ½Å±Ô Ãâ¿ø ±â¾÷ÀÌ °¨¼ÒÇϰí ÀÖ½À´Ï´Ù. °æÀï»çº°·Î´Â Gilead Sciences, BMS, Roche, RegeneronÀÌ B¼¼Æ÷ °¨¼Ò Ä¡·áÁ¦ ºÐ¾ß¿¡¼­ °­·ÂÇÑ Çõ½Å Æ÷Æ®Æú¸®¿À¸¦ º¸À¯ÇÑ ¼±µÎÁÖÀÚÀ̸ç, Abelzeta, Nanjing IASO, Ossianix¿Í °°Àº ½Å»ý±â¾÷µéÀÌ Çõ½ÅÀÇ ¿µÇâ·Â°ú B¼¼Æ÷ °í°¥ ºÐ¾ß¿¡ ´ëÇÑ ÁýÁßµµ Ãø¸é¿¡¼­ ¼±µÎ¸¦ ´Þ¸®°í ÀÖ½À´Ï´Ù. B¼¼Æ÷ °í°¥ Ä¡·áÁ¦ÀÇ ¾à¹° ȯ°æÀº Á¾¾çÇÐ ¹× ¸é¿ªÇÐ Ä¡·áÁ¦¸¦ Áß½ÉÀ¸·Î ÇÑ Çõ½Å ¾à¹°ÀÌ ÁÖ·ù¸¦ ÀÌ·ç°í ÀÖÀ¸¸ç, ºê¸®½ºÅç ¸¶À̾ ½ºÄûºê¿Í ³ë¹ÙƼ½º¿Í °°Àº ´ëÇü Á¦¾à»ç°¡ ¾à¹° °³¹ßÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ¸é¿ªÇÐ ½ÃÇèÀÌ Áß½ÉÀ̸ç, ÅØ»ç½º´ëÇб³ MD ¾Ø´õ½¼ ¾Ï¼¾ÅͰ¡ ½ÃÇè °Ç¼ö¿¡¼­ ¼±µÎ¸¦ ´Þ¸®°í ÀÖ½À´Ï´Ù.

º» º¸°í¼­´Â B¼¼Æ÷ °í°¥¿¡ ´ëÇÑ Ãֽбâ¼ú, ½ÃÀå ºÐ¼®, °æÀï Á¤º¸¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù. ƯÇã, ÀǾàǰ, ÀÓ»ó½ÃÇè, °Å·¡¿¡ ´ëÇÑ »ó¼¼ÇÑ µ¥ÀÌÅ͸¦ Á¦°øÇÏ¿© Àü·« ¼ö¸³¿¡ µµ¿òÀ» µå¸³´Ï´Ù. ÇコÄɾî ÇöȲÀ» ÆÄ¾ÇÇÏ´Â µ¥ Áß¿äÇÑ ±ÔÁ¦ »óȲ°ú ÀÓ»ó °³¹ß °ü·Ã ÃֽŠÁ¤º¸¸¦ Á¦°øÇÕ´Ï´Ù. ¶ÇÇÑ, ±ÝÀ¶ °Å·¡ ¹× ÀÚ±Ý Á¶´Þ µ¿ÇâÀ» ºÐ¼®ÇÏ¿© ÅõÀÚ ±âȸ¸¦ ÆÄ¾ÇÇϰí ÀÌ ºÐ¾ß¿¡¼­ ¿ìÀ§¸¦ È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Çõ½Å ÀλçÀÌÆ®

Á¦2Àå °æÀï ÀλçÀÌÆ®

Á¦3Àå ½ÃÀå ÀλçÀÌÆ®

KSM
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

B cell depletion is a therapeutic strategy aimed at reducing the number of B lymphocytes, which play a crucial role in autoimmune diseases and certain cancers. This approach is primarily used to treat conditions like rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. B cells contribute to disease by producing autoantibodies, presenting antigens, and secreting cytokines. Therapies often target CD20, a marker on B cells, using monoclonal antibodies such as rituximab. However, these treatments typically do not affect long-lived plasma cells, which can continue to produce autoantibodies. Emerging therapies, including chimeric antigen receptor (CAR) T cells, show promise in achieving deeper B cell depletion by targeting CD19, affecting both naive and memory B cells as well as short-lived plasma cells. Your report, which includes patents, drugs, clinical trials, and deals data, provides a comprehensive overview of the current landscape and future directions in B cell depletion therapy.

Key Highlights

Scope

Reasons to Buy

Table of Contents

Table of Contents

1. Innovation Insights

2. Competitive Insights

3.Market Insights

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â